Pharmacology

doi: 10.25005/2074-0581-2019-21-3-450-454
ANTI-TUMOR ACTIVITY OF DRY EXTRACT PADUS GRAYANAE MAXIM IN VITRO

I.Z. Ismailov, A.Z. Zurdinov, T.S. Sabirova

Department of Basic and Clinical Pharmacology, I.K. Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyz Republic

Objective: To study the antitumor activity of dry extract Padus Grayanae Maxim in vitro conditions.

Methods: The object of the study was dry extract Padus Grayanae Maxim, obtained by lyophilic drying method from water-alcohol extraction of plant medicinal raw materials and standardized in content chlorogenic and coffee acids. The study of the cytotoxicity of Padus Grayanae Maxim dry extract conducted on cultures of tumor cells that were derived from the American Type Culture Collection (ATCC). Cell mortality was assessed using the MTT test to form a non-soluble formazan.

Results: It has been established that the studied phytoextraction an antitumor effect in relation to the lines of tumor cells of human cervical adenocarcinoma (HeLa), stomach adenocarcinoma (AGS), human pancreatic carcinoma (MiaPaCa2) and rhabdomyosarcoma of mice (RD). At the same time, fairly high specificity of the action of the studied phytoextraction revealed in relation to the tumor cells adenocarcinoma of the human stomach (AGS). The cell line of tumor cells of human hepatocellular carcinoma (HepG2) has shown resistance to dry extract Padus Grayanae Maxim.

Conclusion: The antitumor effect of the dry extract Padus Grayanae Maxim in vitro conditions has been revealed. At the same time, a specific action against various tumor strains may be due to flavonoids, chlorogenic and coffee acids, which have a wide range of cytotoxicity.

Keywords: Dry extract Padus Grayanae Maxim, antitumor activity, flavonoids, chlorogenic acid, coffee acid.

Download file:


References
  1. Moiseenko VM. (red.) Prakticheskie rekomendatsii po lekarstvennomu lecheniyu zlokachestvennykh opukholey (RUSSCO) [Practical recommendations for the treatment of malignant tumors (RUSSCO)]. Moscow, RF: Rossiyskoe obshchestvo klinicheskoy onkologii; 2015. 456 p.
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians. 2018;68(6):394-424.
  3. Sambukova TV, Ovchinnikov BV, Ganapolskiy VP, Yatmanov AN, Shabanov PD. Perspektivy ispol’zovaniya fitopreparatov v sovremennoy farmakologii [Prospects for the use of herbal remedies in modern pharmacology]. Obzory po klinicheskoy farmakologii i lekarstvennoy terapii. 2017;15(2):56-63.
  4. Selimzyanova LR, Vishnyova EA, Fedoseenko MV, Promyslova EA. Fitoterapiya: sovremennoe sostoyanie voprosa [Herbal medicine: current status of the issue]. Pediatricheskaya farmakologiya. 2016;13(5):488-93.
  5. WHO traditional medicine strategy 2002–2005. 2002;1:74. URL: http://www. who.int/medicines/publications/traditionalpolicy/en/.
  6. Ismailov IZ, Zurdinov AZ, Sabirova TS. Razrabotka i primenenie immunomodulyatorov na sovremennom etape: problemy i perspektivy [Development and use of immunomodulators at the present stage: problems and prospects]. Nauchnyy zhurnal. 2017;1:83-7.
  7. Bosch-Barrera J, Menendez JA. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev. 2015;41(6):540-6.
  8. Olaru OT, Venables L, Van De Venter M, Nitulescu GM, Margina D, Spandidos DA, et al. Anticancer potential of selected Fallopia Adans species. Oncology Letters. 2015;10(3):1323-32.
  9. Levytskiy AP, Vertikova EK, Selivanskaya IA. Khlorogenovaya kislota: biokhimiya y fiziologiya [Chlorogenic acid: biochemistry and physiology]. Mikrobiologiya i biotekhnologiya. 2010;2(10):6-20.
  10. Ismailov IZ. Razrabotka tekhnologii polucheniya sukhogo ekstrakta Padus Grayana Maxim [Development of the technology for the production of dry extract Padus Grayana Maxim]. Nauka, tekhnika i obrazovanie. 2016;10:100-2.
  11. Ismailov IZ, Zurdinov AZ, Sabirova TS. Sposob polucheniya sukhogo ekstrakta iz nadzemnykh chastey Padus Grayanae Maxim [A method of obtaining a dry extract from aerial parts of Padus Grayanae Maxim]. Patent № 20170100.1. 28.09.2017.
  12. Ismailov IZ. Izuchenie biologicheski aktivnykh veshchestv Padus Grayanae Maxim i ikh antioksidantnye svoystva VEZHKH [The study of biologically active substances Padus Grayanae Maxim and their antioxidant properties by HPLC]. Vestnik nauki i obrazovaniya. 2017;4:105-9.
  13. Ismailov IZ. Issledovanie soderzhaniya khimicheskikh elementov v fitoekstrakte Padus Grayana Maxim [The study of the content of chemical elements in the phytoextract Padus Grayana Maxim]. Mezhdunarodnyy zhurnal prikladnykh i fundamental’nykh issledovaniy. 2017;7(1):117-20.
  14. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;67(1):7-30.
  15. Dong Y, Cao A, Shi J. Tangeretin, a citrus polymethoxyflavonoid, induces apoptosis of human gastric cancer AGS cells through extrinsic and intrinsic signaling pathways. Oncology Reports. 2014;31(4):1788-94.
  16. Yen GC, Chen CS, Chang WT, Wu MF, Cheng FT, Shiau DK, et al. Antioxidant activity and anticancer effect of ethanolic and aqueous extracts of the roots of Ficus beecheyana and their phenolic components. Journal of Food and Drug Analysis. 2018;26(1):182-92.

Authors' information:


Ismailov Isabek Zaylidinovich
Doctor of Pharmaceutical Sciences, Associate Professor, Department of Basic and Clinical Pharmacology, I.K. Akhunbaev Kyrgyz State Medical Academy
ORCID ID: 0000-0002-1468-8251
Author ID: 877010
SPIN: 9540-1750
E-mail: ism-isa@mail.ru

Zurdinov Ashirali Zurdinovich
Doctor of Medical Sciences, Professor of the Department of Basic and Clinical Pharmacology, I.K. Akhunbaev Kyrgyz State Medical Academy
ORCID ID: 0000-0002-7110-0901
Author ID: 877038
SPIN: 3719-0291
E-mail: a-zurdinov@yandex.ru

Sabirova Tamara Semyonovna
Candidate of Medical Sciences, Associate Professor, Department of Basic and Clinical Pharmacology, I.K. Akhunbaev Kyrgyz State Medical Academy
ORCID ID: 0000-0002-3709-0244
Author ID: 877003
SPIN: 1684-5129
E-mail: sabirova_ts@mail.ru

Information about support in the form of grants, equipment, medications

The work was carried out according to the plan of scientific research works of I.K. Akhunbaev Kyrgyz State Medical Academy (state registration number – 0004828). The authors did not receive financial support from manufacturers of medicines and medical equipment.

Conflicts of interest: No conflict

Address for correspondence:


Ismailov Isabek Zaylidinovich
Doctor of Pharmaceutical Sciences, Associate Professor, Department of Basic and Clinical Pharmacology, I.K. Akhunbaev Kyrgyz State Medical Academ

720020, Kyrgyz Republic, Bishkek, Akhunbaev Street, 92

Tel.: +996 (559) 639 777

E-mail: ism-isa@mail.ru

Materials on the topic: